Long acting GLP-1 receptor agonist (injectable)
Liraglutide 1.8 mg subcutaneous once daily
LIRA_SC_1p8MG_QD
Related
- All doses pooled: Liraglutide injection
- Liraglutide flexible dose injection once daily
- Liraglutide 3.0 mg subcutaneous once daily
- Liraglutide maximum tolerated dose injection once daily
- Liraglutide 0.9 mg injection once daily
- Liraglutide flexible dose injection once daily
- Liraglutide 1.2 mg subcutaneous once daily
- Liraglutide maximum tolerated dose injection once daily
- Liraglutide 0.6 mg subcutaneous once daily
- Liraglutide subcutaneous once daily, flexible dose: 1.2 or 1.8 mg by tolerability
- Liraglutide 2.4 mg injection once daily
- Liraglutide maximum tolerated dose injection once daily
- Liraglutide maximum tolerated dose injection once daily
- Liraglutide 0.6 mg injection
- Liraglutide 1.2 mg injection
- Liraglutide 1.25UG/KG injection once daily
- Liraglutide 5.0UG/KG injection once daily
- Liraglutide 7.5UG/KG injection once daily
- Liraglutide 10UG/KG injection once daily
- Liraglutide 12.5UG/KG injection once daily
- Liraglutide 0.3 mg injection once daily
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Type 2 diabetes (adults) | HbA1c change | weeks 20 to 36 (target week 26) | Placebo | MD -1.07 (-1.34 to -0.79) | 0.62 |
| Type 2 diabetes (adults) | HbA1c change | weeks 20 to 36 (target week 26) | Placebo | MD -1.06 (-1.25 to -0.86) | 0.69 |
| Type 2 diabetes (adults) | HbA1c change | weeks 36 to 64 (target week 52) | Placebo | MD 0.23 (-0.16 to 0.69) | 0.36 |
| Type 2 diabetes (adults) | HbA1c change | weeks 36 to 64 (target week 52) | Placebo | MD -0.79 (-1.21 to -0.31) | 0.64 |
| Type 2 diabetes (adults) | HbA1c change | weeks 20 to 36 (target week 26) | Placebo | MD -1.51 (-1.98 to -0.27) | 0.73 |
| Type 2 diabetes (adults) | HbA1c change | weeks 20 to 36 (target week 26) | Placebo | MD -0.91 (-1.29 to -0.50) | 0.67 |
| Type 2 diabetes (adults) | HbA1c change | weeks 20 to 36 (target week 26) | Placebo | MD -1.18 (-1.76 to -0.46) | 0.74 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 20 to 36 (target week 26) | Placebo | MD -2.10 (-2.88 to -1.33) | 0.60 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 36 to 64 (target week 52) | Placebo | MD -1.34 (-3.01 to 0.84) | 0.53 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 20 to 36 (target week 26) | Placebo | MD -1.69 (-2.41 to -1.02) | 0.72 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 36 to 64 (target week 52) | Placebo | MD -2.07 (-3.56 to -0.45) | 0.61 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 20 to 36 (target week 26) | Placebo | MD 1.84 (-1.19 to 9.55) | 0.17 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 20 to 36 (target week 26) | Placebo | MD -2.40 (-3.42 to -1.42) | 0.69 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 20 to 36 (target week 26) | Placebo | MD -3.05 (-7.71 to 1.69) | 0.69 |
| Type 2 diabetes (adults) | HbA1c below 7 percent | weeks 20 to 36 (target week 26) | Placebo | OR 8.28 (2.57 to 20.90) | 0.61 |
| Type 2 diabetes (adults) | HbA1c below 7 percent | weeks 36 to 64 (target week 52) | Semaglutide 1.0 mg subcutaneous once weekly | OR 0.45 (0.18 to 1.43) | 0.38 |
| Type 2 diabetes (adults) | HbA1c below 7 percent | weeks 36 to 64 (target week 52) | Placebo | OR 5.97 (1.60 to 15.39) | 0.78 |
| Type 2 diabetes (adults) | HbA1c below 7 percent | weeks 36 to 64 (target week 52) | Placebo | OR 5.81 (2.13 to 12.43) | 0.76 |
| Type 2 diabetes (adults) | HbA1c below 7 percent | weeks 20 to 36 (target week 26) | Placebo | OR 4.73 (1.85 to 9.70) | 0.59 |
| Type 2 diabetes (adults) | HbA1c below 7 percent | weeks 20 to 36 (target week 26) | Placebo | OR 8.09 (3.17 to 17.97) | 0.80 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 0.29 (0.06 to 1.08) | 0.56 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 4.49 (1.37 to 14.21) | 0.28 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 1.22 (0.61 to 2.29) | 0.56 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 0.89 (0.50 to 1.55) | 0.52 |
| Type 2 diabetes (adults) | Systolic blood pressure change | weeks 20 to 36 (target week 26) | Placebo | MD -3.41 (-4.57 to -2.18) | 0.71 |
| Type 2 diabetes (adults) | Systolic blood pressure change | weeks 36 to 64 (target week 52) | Placebo | MD 3.52 (-2.04 to 9.09) | 0.45 |
| Type 2 diabetes (adults) | Systolic blood pressure change | weeks 36 to 64 (target week 52) | Placebo | MD -2.89 (-8.32 to 2.87) | 0.56 |
| Type 2 diabetes (adults) | Systolic blood pressure change | weeks 20 to 36 (target week 26) | Placebo | MD -1.65 (-5.08 to 1.52) | 0.83 |
| Type 2 diabetes (adults) | Systolic blood pressure change | weeks 20 to 36 (target week 26) | Placebo | MD -4.13 (-7.89 to -0.38) | 0.65 |
| Type 2 diabetes (adults) | Percent body weight change | weeks 40 to 104 (target week 68) | Semaglutide 14 mg oral once daily (original tablet) | MD 2.15 (-5.15 to 9.07) | 0.20 |
| Type 2 diabetes (adults) | Percent body weight change | weeks 40 to 104 (target week 68) | Placebo | MD -2.21 (-4.44 to 0.17) | 0.54 |
| Type 2 diabetes (adults) | Percent body weight change | weeks 20 to 40 (target week 26) | Placebo | MD -2.70 (-4.38 to -0.80) | 0.69 |
| Type 2 diabetes (adults) | Percent body weight change | weeks 20 to 40 (target week 26) | Placebo | MD -1.20 (-10.36 to 8.82) | 0.41 |
| Type 2 diabetes (adults) | Percent body weight change | weeks 20 to 40 (target week 26) | Placebo | MD -2.59 (-6.52 to 2.44) | 0.56 |
| Type 2 diabetes (adults) | Percent body weight change | weeks 40 to 104 (target week 68) | Placebo | MD -1.19 (-5.86 to 5.83) | 0.43 |
| Type 2 diabetes (adults) | Weight loss of 5 percent or more | weeks 20 to 40 (target week 26) | Placebo | OR 4.21 (1.50 to 11.16) | 0.52 |
| Type 2 diabetes (adults) | Weight loss of 5 percent or more | weeks 40 to 104 (target week 68) | Placebo | OR 2.28 (0.78 to 6.26) | 0.58 |
| Type 2 diabetes (adults) | Weight loss of 5 percent or more | weeks 20 to 40 (target week 26) | Placebo | OR 3.94 (1.39 to 10.26) | 0.74 |
| Type 2 diabetes (adults) | Weight loss of 5 percent or more | weeks 40 to 104 (target week 68) | Placebo | OR 2.06 (0.83 to 4.88) | 0.48 |
| Type 2 diabetes (adults) | Weight loss of 5 percent or more | weeks 40 to 104 (target week 68) | Placebo | OR 2.44 (0.71 to 5.97) | 0.38 |
| Type 2 diabetes (adults) | Weight loss of 10 percent or more | weeks 20 to 40 (target week 26) | Placebo | OR 5.00 (1.12 to 25.69) | 0.58 |
| Type 2 diabetes (adults) | Weight loss of 10 percent or more | weeks 40 to 104 (target week 68) | Placebo | OR 2.09 (0.52 to 8.63) | 0.57 |
| Type 2 diabetes (adults) | Weight loss of 10 percent or more | weeks 20 to 40 (target week 26) | Placebo | OR 4.58 (1.16 to 19.74) | 0.67 |
| Type 2 diabetes (adults) | Weight loss of 10 percent or more | weeks 40 to 104 (target week 68) | Placebo | OR 2.10 (0.65 to 6.78) | 0.59 |
| Type 2 diabetes (adults) | Weight loss of 10 percent or more | weeks 40 to 104 (target week 68) | Semaglutide 1.0 mg subcutaneous once weekly | OR 0.26 (0.10 to 0.80) | 0.33 |
| Type 2 diabetes (adults) | Three point MACE | longest follow-up | Placebo | HR 0.96 (0.20 to 4.55) | 0.46 |
| Type 2 diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 0.78 (0.65 to 0.93) | 0.64 |
| Type 2 diabetes (adults) | Discontinuation due to adverse events | longest follow-up | Placebo | HR 1.95 (1.27 to 3.01) | 0.43 |
| Type 2 diabetes (adults) | Nausea | longest follow-up | Placebo | HR 3.43 (2.84 to 4.15) | 0.39 |
| Type 2 diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 2.78 (2.09 to 3.67) | 0.49 |
| Type 2 diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 1.88 (1.56 to 2.27) | 0.42 |
| Type 2 diabetes (adults) | Constipation | longest follow-up | Placebo | HR 1.71 (1.23 to 2.38) | 0.49 |
| Type 2 diabetes (adults) | Discontinuation due to gastrointestinal adverse events | longest follow-up | Placebo | HR 4.48 (2.03 to 10.97) | 0.26 |
| Type 2 diabetes (adults) | Acute pancreatitis | longest follow-up | Placebo | HR 0.21 (0.04 to 1.06) | 0.78 |
| Type 2 diabetes (adults) | Diabetic retinopathy complications | longest follow-up | Placebo | HR 0.73 (0.15 to 3.50) | 0.64 |
| Type 2 diabetes (adults) | Pancreatic cancer | longest follow-up | Placebo | HR 1.74 (0.24 to 12.63) | 0.31 |
| Type 2 diabetes (adults) | Any cancer | longest follow-up | Placebo | HR 0.84 (0.12 to 4.52) | 0.61 |
| Type 2 diabetes (adults) | Acute kidney injury | longest follow-up | Placebo | HR 2.83 (0.10 to 72.03) | 0.28 |
| Overweight or obesity without diabetes (adults) | Systolic blood pressure change | weeks 40 to 104 (target week 68) | Placebo | MD 0.51 (-5.64 to 6.63) | 0.15 |
| Overweight or obesity without diabetes (adults) | Systolic blood pressure change | weeks 20 to 40 (target week 26) | Placebo | MD -2.16 (-11.63 to 7.35) | 0.37 |
| Overweight or obesity without diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 2.55 (1.08 to 6.28) | 0.26 |
| Overweight or obesity without diabetes (adults) | Nausea | longest follow-up | Placebo | HR 2.72 (1.88 to 3.93) | 0.66 |
| Overweight or obesity without diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 3.15 (1.58 to 6.23) | 0.62 |
| Overweight or obesity without diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 1.08 (0.45 to 2.50) | 0.73 |
| Overweight or obesity without diabetes (adults) | Constipation | longest follow-up | Placebo | HR 1.29 (0.51 to 3.14) | 0.67 |
| Type 1 diabetes | HbA1c change | weeks 12 to 40 (target week 26) | Placebo | MD -0.25 (-0.75 to 0.38) | 0.64 |
| Type 1 diabetes | Serious adverse events | longest follow-up | Placebo | HR 0.82 (0.45 to 1.51) | 0.68 |
| Type 1 diabetes | Nausea | longest follow-up | Placebo | HR 4.48 (2.83 to 6.89) | 0.05 |
| Type 1 diabetes | Vomiting | longest follow-up | Placebo | HR 3.74 (1.96 to 7.02) | 0.04 |
| Type 1 diabetes | Diarrhea | longest follow-up | Placebo | HR 1.78 (1.05 to 3.10) | 0.06 |
| Type 1 diabetes | Constipation | longest follow-up | Placebo | HR 2.15 (0.97 to 4.68) | 0.30 |
| Chronic kidney disease with diabetes | Serious adverse events | longest follow-up | Placebo | HR 0.93 (0.27 to 3.22) | 0.65 |
| Chronic kidney disease with diabetes | Nausea | longest follow-up | Placebo | HR 5.08 (1.27 to 18.34) | 0.27 |
| Chronic kidney disease with diabetes | Vomiting | longest follow-up | Placebo | HR 5.41 (1.13 to 25.85) | 0.36 |
| Chronic kidney disease with diabetes | Diarrhea | longest follow-up | Placebo | HR 2.42 (0.52 to 11.76) | 0.50 |
| Chronic kidney disease with diabetes | Constipation | longest follow-up | Placebo | HR 3.58 (0.63 to 24.60) | 0.27 |
| Polycystic ovary syndrome | Nausea | longest follow-up | Placebo | HR 10.66 (3.95 to 29.47) | 0.02 |
| Polycystic ovary syndrome | Diarrhea | longest follow-up | Placebo | HR 2.40 (0.51 to 14.77) | 0.37 |
| Polycystic ovary syndrome | Constipation | longest follow-up | Placebo | HR 23.10 (3.46 to 344) | 0.02 |
Trials
- S003425115 randomized · 13.04 weeks
- S00307060 randomized · 2 weeks
- S0034322020 · 218 randomized · 52 weeks
- S0031002019 · 90 randomized · 13.04 weeks
- NCT03555994An Exploratory Phase 2, Randomised, Double-blind, Placebo-controlled, and Open-label Active Comparator Study to Evaluate the Effect of MEDI0382 on Hepatic Glycogen Metabolism in Overweight and Obese Subjects With Type 2 Diabetes Mellitus.2018 · 51 randomized · 5 weeks
- S0029692018 · 27 randomized · 26 weeks
- DUAL™ I ChinaA Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide, Insulin Degludec, and Liraglutide in Chinese Subjects With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetic Drugs (OADs)2017 · 720 randomized · 26 weeks
- NCT03878706The Effect of GLP-1 Agonist, SGLT2 Inhibitor and Their Combination on Endothelial Function, Arterial Stiffness and Left Ventricular Deformation in Patients With Type 2 Diabetes With High Cardiovascular Risk2017 · 180 randomized · 52.14 weeks
- LIRAFLAMEEffect of Liraglutide on Vascular Inflammation in Type-2 Diabetes: A Randomized, Placebo-controlled, Double-blind, Parallel Clinical PET/CT Trial The Liraflame Trial2017 · 102 randomized · 26 weeks
- NCT02960659Therapeutic Targets in African-American Youth With Type 2 Diabetes2017 · 24 randomized · 12 weeks
- NCT03101930Cardiovascular Effects of GLP-1 Receptor Activation2017 · 93 randomized · 14 weeks
- NCT03235050A Phase IIb, Randomised, Parallel, Double-Blind Placebo-Controlled and Open-Label Active Comparator Study to Evaluate the Efficacy and Safety of MEDI0382 in the Treatment of Overweight and Obese Subjects With Type 2 Diabetes Mellitus2017 · 834 randomized · 54 weeks
- NCT02973321A 26-Week Randomized, Double-blind, Placebo-controlled, Dose-ranging Phase 2 Study to Assess the Safety and Efficacy of SAR425899 in Patients With Type 2 Diabetes Mellitus2016 · 296 randomized · 26 weeks
- PIONEER 4Efficacy and Safety of Oral Semaglutide Versus Liraglutide and Versus Placebo in Subjects With Type 2 Diabetes Mellitus2016 · 711 randomized · 52 weeks
- NCT03010683Effects of Agonists of Glucagon Like Peptide - 1 Receptors (GLP-1R) on Arterial Stiffness, Endothelial Glycocalyx and Coronary Flow Reserve in Patients With Coronary Artery Disease and Patients With Diabetes Mellitus2015 · 60 randomized · 26.07 weeks
- MAGNA VICTORIAMagnetic Resonance Assessment of Victoza Efficacy in the Regression of Cardiovascular Dysfunction In Type 2 Diabetes Mellitus and South Asian Descent2015 · 47 randomized · 26 weeks
- NCT02765399The Effect of Liraglutide Treatment on Postprandial Chylomicron and VLDL Kinetics, Liver Fat and de Novo Lipogenesis - a Single-center Randomized Controlled Study2015 · 23 randomized · 16 weeks
- NCT02617654A Randomized, Double-blinded Placebo-controlled, Paralleled Designed, Investigator Sponsored Study of the Effect of the GLP-1 Receptor Agonist Liraglutide on Beta-cell Function in C-peptide Positive Type 1 Diabetic Patients2015 · 18 randomized · 52 weeks
- DUAL™ I JapanA Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide, Insulin Degludec and Liraglutide in Japanese Subjects With Type 2 Diabetes Mellitus2015 · 819 randomized · 52 weeks
- NCT02505334A Trial Comparing the Efficacy and Safety of Liraglutide 1.8 mg/Day to Liraglutide 0.9 mg/Day in Japanese Subjects With Type 2 Diabetes Mellitus2015 · 466 randomized · 26 weeks
- ELADEvaluating the Effects of the Novel GLP-1 Analogue, Liraglutide, in Patients With Mild Alzheimer's Disease (ELAD Study)2014 · 204 randomized · 52 weeks
- S0031012014 · 72 randomized · 26 weeks
- ADJUNCT TWO™A 26-weeks Randomised, Insulin Capped, Placebo-controlled, Double-blind, Parallel Group, Multinational, Multi-centre Trial2014 · 835 randomized · 26 weeks
- NCT02490176Effects of Liraglutide on Hemodynamic Parameters in Patients With Heart Failure2014 · 52 randomized · 1 weeks
- NCT02324842Effect of Combined Incretin-Based Therapy Plus Canagliflozin on Glycemic Control and the Compensatory Rise in Hepatic Glucose Production in Type 2 Diabetic Patients2014 · 45 randomized · 16 weeks
- NCT03068065Comparison of Efficacy of Liraglutide, Metformin and Gliclazide MR on Hepatic Lipid Content in Patients With Type 2 Diabetes (T2DM) and Non-alcoholic Fatty Liver (NAFLD)2014 · 93 randomized · 24 weeks
- LIGHT-ONEfficacy of Liraglutide vs. Sitagliptin vs. Insulin Glargine Per Day on Liver Fat When Combined With Metformin in T2DM Subjects With Non-alcoholic Fatty-liver Disease2014 · 75 randomized · 26 weeks
- LIPTA Randomised, Double-blind, Placebo-controlled Study of the Effect of Liraglutide in Polycystic Ovary Syndrome on Risk Markers of Vascular Thrombosis.2014 · 72 randomized · 26 weeks
- LIRA-Ramadan™Efficacy and Safety of Liraglutide Versus Sulphonylurea Both in Combination With Metformin During Ramadan in Subjects With Type 2 Diabetes2014 · 343 randomized · 30 weeks
- NCT02008682The Efficacy and Safety of Liraglutide Compared to Sitagliptin, Both in Combination With Metformin in Chinese Subjects With Type 2 Diabetes.(LIRA-DPP-4 CHINA™)2013 · 368 randomized · 26 weeks
- GRADEGlycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study2013 · 5,047 randomized · 365.26 weeks
- LIRA-SWITCH™Efficacy and Safety of Switching From Sitagliptin to Liraglutide in Subjects With Type 2 Diabetes Not Achieving Adequate Glycaemic Control on Sitagliptin and Metformin2013 · 407 randomized · 26 weeks
- NCT02059564A Phase 1b, Exploratory, Randomized, Partially Single Blinded, Placebo and Open Label Controlled, Parallel Group Study to Assess the Effects of HM11260C and an Active Comparator on Gastric Emptying and Beta-Cell Response in Subjects With Type 2 Diabetes Mellitus2013 · 47 randomized · 13 weeks
- ADJUNCT ONE™The Efficacy and Safety of Liraglutide as Adjunct Therapy to Insulin in the Treatment of Type 1 Diabetes. A 52-week Randomised, Treat-to-target, Placebo-controlled, Double Blinded, Parallel Group, Multinational, Multi-centre Trial2013 · 1,398 randomized · 52 weeks
- NCT02113332Addition of Liraglutide to Overweight Patients With Type 2 Diabetes Treated With Multiple Daily Insulin Injections (MDI) With Inadequate Glycaemic Control2013 · 124 randomized · 24 weeks
- NCT01425580Effects on Subclinical Heart Failure in Type 2 Diabetic Subjects on Liraglutide Treatment Versus Glimepiride Both in Combination With Metformin2012 · 62 randomized · 18 weeks
- NCT01617434The Effect of Liraglutide Versus Placebo When Added to Basal Insulin Analogues With or Without Metformin in Subjects With Type 2 Diabetes2012 · 451 randomized · 26 weeks
- AWARD-6A Randomized, Open-Label, Parallel-Arm Study Comparing the Effect of Once-Weekly Dulaglutide With Once-Daily Liraglutide in Patients With Type 2 Diabetes (AWARD-6: Assessment of Weekly AdministRation of LY2189265 in Diabetes-6)2012 · 599 randomized · 26 weeks
- NCT01795248The Impact of Liraglutide on Glucose Tolerance and the Risk of Type 2 Diabetes in Women With Previous Gestational Diabetes Mellitus2012 · 104 randomized · 52 weeks
- NCT01620489Efficacy and Safety of Liraglutide Versus Placebo as add-on to Existing Diabetes Medication in Subjects With Type 2 Diabetes and Moderate Renal Impairment. A 26-week Double-blind Placebo-controlled, Randomised, Multicentre, Multi-national, Parallel-group Trial2012 · 279 randomized · 26 weeks
- NCT01753362LIRAGLUTIDE IN OVERWEIGHT PATIENTS WITH TYPE 1 DIABETES2012 · 85 randomized · 26 weeks
- ELEGANTThe Effect of Liraglutide on Insulin-associated wEight GAiN in Patients With Type 2 Diabetes Mellitus (ELEGANT Trial)2012 · 50 randomized · 26 weeks
- S0031082012 · 24 weeks
- NCT01272232Effect of Liraglutide on Body Weight in Overweight or Obese Subjects With Type 2 Diabetes: A 56 Week Randomised, Double-blind, Placebo-controlled, Three Armed Parallel Group, Multi-centre, Multinational Trial With a 12 Week Observational Follow-up Period2011 · 846 randomized · 56 weeks
- NCT01455441Does the GLP-1 Receptor Agonist (Victoza®) Improve the Metabolic Response to Physical Training in Patients With Type 2 Diabetes?2011 · 36 randomized · 16 weeks
- NCT01175473An Open-label, Randomized Two-arm Parallel Group Study to Compare the Effects of 4-week QD Treatment With Lixisenatide or Liraglutide on the Postprandial Plasma Glucose in Patients With Type 2 Diabetes Not Adequately Controlled With Metformin2010 · 148 randomized · 4 weeks
- NCT01029886Safety and Efficacy of Exenatide Once Weekly Versus Liraglutide in Subjects With Type 2 Diabetes and Inadequate Glycemic Control Treated With Lifestyle Modification and Oral Antidiabetic Medications2010 · 912 randomized · 26 weeks
- NCT01784965Addition of a Glucagon-like Peptide-1 to a Calorie Restricted Diet Augments Weight Loss and Decreases Risk of Type 2 Diabetes and Cardiovascular Disease.2009 · 68 randomized · 14 weeks
- NCT00700817The Effect of Liraglutide Compared to Sitagliptin, Both in Combination With Metformin in Subjects With Type 2 Diabetes. A 26-week, Randomised, Open-label, Active Comparator, Three-armed, Parallel-group, Multi-centre, Multinational Trial With a 52-week Extension2008 · 665 randomized · 26 weeks
- LEAD-6Effect of Liraglutide or Exenatide Added to a Background Treatment of Metformin, Sulphonylurea or a Combination of Both on Glycaemic Control in Subjects With Type 2 Diabetes2007 · 464 randomized · 26 weeks
- S0030672007 · 564 randomized · 52 weeks
- NCT00422058Effect of Liraglutide on Body Weight in Obese Subjects Without Diabetes: A 20-week Randomised, Double-blind, Placebo-controlled, Six Armed Parallel Group, Multi-centre, Multinational Trial With an Open Label Orlistat Comparator Arm and With an 84-week Extension Period2007 · 564 randomized · 52 weeks
- LEAD-2Liraglutide Effect and Action in Diabetes (LEAD-2): Effect on Glycaemic Control After Once Daily Administration of Liraglutide in Combination With Metformin Versus Metformin Monotherapy Versus Metformin and Glimepiride Combination Therapy in Subjects With Type 2 Diabetes2006 · 1,091 randomized · 26 weeks
- LEAD-5Liraglutide Effect and Action in Diabetes (LEAD-5): Effect on Glycaemic Control After Once Daily Administration of Liraglutide in Combination With Glimepiride and Metformin Versus Glimepiride and Metformin Combination Therapy, and Versus Insulin Glargine Added to Glimepiride and Metformin Combination Therapy in Subjects With Type 2 Diabetes.A Six-month Randomised, Double-blind, Parallel-group, Multi-centre, Multi-national Trial With an Open-label Treat-to-target Insulin Glargine Control Arm.2006 · 581 randomized · 26 weeks